Dynavax to Present at UBS Global Life Sciences Conference
Posted on: Thursday, 21 September 2006, 18:01 CDT
BERKELEY, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation announced that Deborah Smeltzer, Vice President, Operations and CFO, will present an overview of the company at the UBS Global Life Sciences conference, September 26, 2006 at 4:00 p.m. Eastern, in New York City. The webcast presentation may be accessed by visiting http://events.streamx.us/US/event/EventDetails.aspx?id=ubs20060925 .
The presentation may also be accessed by visiting the Dynavax website at http://www.dynavax.com/ under the Investors section .
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR-9 agonist-based products to treat and prevent allergies, infectious diseases, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA(TM), a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a supportive clinical trial in ragweed allergic children; HEPLISAV(TM), a hepatitis B vaccine in Phase 3; and a therapy for non-Hodgkins lymphoma in Phase 2. Its preclinical asthma and COPD programs are partnered with AstraZeneca.
Funding for the company's other preclinical programs in cancer, hepatitis B and hepatitis C therapies, and for an influenza vaccine have been provided by Symphony Dynamo and NIH, but represent future partnering opportunities.
Dynavax Technologies Corporation
CONTACT: Shari Annes, Corporate Communications of Dynavax TechnologiesCorporation, +1-650-888-0902, or sannes@dvax.com
Web site: http://www.dynavax.com/
Source: PRNewswire-FirstCall
Related Articles
- Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
- Airservices Australia Selects Sensis/NAV CANADA Team for National Tower Program Technology Project
- Presidio Pharmaceuticals Receives Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
- Biophysical Launches Biophysical250 Corporate Program
- Research and Markets: Xerox Corporation Is A Technology And Services Enterprise, Which Develops, Manufactures, Markets, Services And Finances A Range Of Document Equipment
- Dynavax to Advance Cancer, Hepatitis B and Hepatitis C Therapy Programs With $50 Million Funding
- infoUSA Appoints Dan Speicher As the Corporate Chief Technology Officer
- TicketsNow Names John Ketchum Vice President, Corporate Programs
- Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program
- Numbers in Corporate Program Rebound
 |
 |
User Comments (0)
RSS Feeds